ユーイング肉腫市場 - 市場の洞察、疫学、市場予測：2034年

主なハイライト

• 2023年、米国は主要7ヶ国のユーイング肉腫治療市場の最大シェア（約53％）を占めました。
• ユーイング肉腫患者の多くは20歳未満であるため、晩期毒性のリスクが少ない分子標的治療が有益です。
• 難治性または再発ユーイング肉腫に対する標準的な二次治療はありませんが、いくつかのレトロスペクティブ研究が従来の救済療法について報告しています。
• 現在、ユーイング肉腫の治療では化学療法と局所療法（手術および/または放射線療法）が主流です。
• VDC/IEレジメンの採用により生存期間は有意に延長しました。転移性ユーイング肉腫の患者は依然として予後不良であり、将来の治療薬に対する需要が高まると予測されます。
• ユーイング肉腫の予後は、治療の進歩により年々改善されています。限局性ユーイング肉腫の5年生存率は約70～80％であるのに対し、転移性疾患の生存率は約30～40％と低いです。しかし、生存率は個々の要因や治療への反応別変化することに注意することが重要です。
• NCCNガイドラインの最新版2.2023では、ユーイング肉腫の2次治療としてルルビネクチンが追加されました（R/Rまたは転移性病変の場合）。
• ユーイング肉腫にはまだ治療薬が承認されていないため、この領域に参入し、先行者利益を獲得する企業には大きな市場機会があります。
• 標的ユーイング肉腫治療、免疫療法、精密腫瘍学、その他の新規治療が一部のがん種の治療に用いられているが、多くの肉腫亜型では依然として化学療法が治療の主流です。肉腫の多くの亜型に対して、特に病勢進行後に患者に効果的に投与できる治療薬は、承認されていないか、あるいは非常に少ないです。
• 適応外治療の使用は新しい治療法の普及を妨げる可能性があります。
• 転移性ユーイング肉腫に対する第一選択療法は、限局性病変に対するものと同様であり、原発部位と転移部位の両方に十分な局所制御が可能な同じ化学療法のバックボーンを利用します。
• ユーイング肉腫治療薬の開発は、主にSalarius Pharmaceuticals、Jazz Pharmaceuticals、Pfizer、Eli Lilly and Company、BioAlta、Inhibrxなどの著名なユーイング肉腫企業により行われています。これらの主なユーイング肉腫企業は、セカンドライン（2L）以上の患者を対象とした治療開発に注力しています。
• 予期せぬ重大な有害反応（SUSAR）の可能性があったため、Salariusは昨年、ユーイング肉腫の治療薬としてセクリデムスタットの第I/II相臨床試験の新規患者の登録を自主的に中止しました。FDAは2023年5月に同社のseclidemstatの申請に対する審査を終了し、臨床試験を再開する可能性があると宣言しました。

当レポートは、米国、EU4ヶ国（ドイツ、フランス、イタリア、スペイン）、英国、日本におけるユーイング肉腫の歴史的および予測疫学、ならびにユーイング肉腫の市場動向を詳細にお届けします。

現在の治療法、新薬、各治療法のユーイング肉腫市場シェア、2020年から2034年までの主要7ヶ国ユーイング肉腫市場規模の現状と予測を提供します。また、現在のユーイング肉腫治療薬の市場慣行/アルゴリズムや、ユーイング肉腫のアンメットメディカルニーズも網羅し、最良の機会を発掘し、市場の可能性を評価します。

ユーイング肉腫は、通常、骨の中で増殖を開始するがん性腫瘍です。主に小児および若年成人に発生し、多くの場合10代で発症します。ユーイング肉腫はどの骨にも発生しますが、通常は大腿骨、脛骨、上腕骨などの長い骨に発生します。骨盤の骨もしばしば侵されます。時には、腫瘍が筋肉や軟部組織から始まることもあります。最も一般的な症状は、骨や骨周囲の組織のこわばり、痛み、腫れ、圧痛です。

患者の症状としては、安静にしていても続く骨の痛み、腫れ、患部の骨に大きな腫瘤があるなどの症状から始まります。その後、整形外科を受診し、MRI、CTスキャン、単純X線撮影などの診断検査を提案されます。診断後、患者はさらなる治療のために腫瘍専門医に紹介されます。確定診断のために、画像診断で判断されたがんの最も進行した部分から摘出された腫瘤の組織生検が行われます。ユーイング肉腫が確定されると、患者さんに適切な治療が行われます。

ユーイング肉腫の治療には一般的に、手術、化学療法、放射線療法を含む集学的アプローチが用いられます。NCCNは、限局性および転移性ユーイング肉腫の治療に異なる化学療法の組み合わせを推奨しています。VDC/IE（ビンクリスチン、ドキソルビシン、シクロホスファミドとイホスファミド、エトポシドの交互投与）、VAIA（ビンクリスチン、ドキソルビシン、イホスファミド、ダクチノマイシン）、VIDE（ビンクリスチン、イホスファミド、ドキソルビシン、エトポシド）は、NCCNにより初回治療および転移性疾患の一次治療として推奨されています。二次治療としては、シクロホスファミドとトポテカン、イリノテカン＋テモゾロミド＋-、NCCNはビンクリスチン、イホスファミド、カルボプラチン、エトポシド、ルルビネクチンを推奨しています。

• 主要7ヶ国において、ユーイング肉腫の罹患数が最も多いのは米国で、全罹患数の約41％を占めています。
• EU4ヶ国では、ユーイング肉腫の罹患数が最も多かったのはドイツで、全罹患数の約15%を占め、最も少なかったのはイタリアでした。
• 米国では、すべての年齢層の中で、10～14歳のユーイング肉腫症例数が最も多く、約30％を占め、次いで15～19歳（26％）でした。
• 分析別と、男性は女性よりもユーイング肉腫に罹患する可能性が高いです。米国では、2023年に男性のユーイング肉腫の偶発症例が300件程度発生すると推定されています。

ユーイング肉腫の最近の動向

• 2024年11月12日、Actuate Therapeutics, Incは、ユーイング肉腫（EWS）の治療薬として新規グリコーゲン合成酵素キナーゼ-3β（GSK-3B）阻害薬であるエラグルシブが米国食品医薬品局（FDA）より希少小児疾患指定を受けたと発表しました。
• 2024年11月12日、FDAは新規GSK-3B阻害剤であるエラグルシブ（9-ING-41）をユーイング肉腫患者の治療薬として希少小児疾患指定しました。

• セクリデムスタットSalarius Pharmaceuticals

Seclidemstat（SP-2577）はLSD1の酵素活性とその足場機能を阻害します。SP-2577はユーイング肉腫を対象とした第I/II相試験が進行中です。サラリウス社は、SP-2577とトポテカンおよびシクロホスファミド（TC）との併用療法を研究しており、TC単独療法よりも患者の転帰を改善することを目的としています。

• 2022年10月、同社はユーイング肉腫およびFET再配列肉腫の治療薬としてのセクリデムスタットの第I/II相試験の新規患者登録をプロトコールデザインに従って自主的に一時停止しました。新規患者登録の一時停止は、予期せぬ重篤な有害反応の疑い（SUSAR）として分類された転移性FET再配列肉腫患者の死亡別ものでした。
• その後、2023年5月、同社はFDAから、同社が提出した申請書の審査が完了し、ユーイング肉腫の臨床試験を再開してもよいとの結論を得たとの通知を受けた。
• ZEPZELCA（Lurbinectedin）：Jazz PharmaceuticalsとPharmaMar

Lurbinectedin（PM1183）は現在臨床試験中の合成化合物です。多くの腫瘍が特に依存しているがん原性転写プログラムの選択的阻害剤です。

• 2019年12月、PharmaMar社とJazz Pharmaceuticals社は、米国におけるlurbinectedinの独占的ライセンス契約を締結したと発表しました。
• NCCNガイドラインの更新版2.2023において、lurbinectedinはユーイング肉腫（R/Rまたは転移性疾患の場合）の2次治療の選択肢として追加されました。カテゴリー2Bでは、これは特定の状況下での推奨に有用です。

CDK阻害薬：CDK9、CDK12、CDK13のようなRNAの転写、プロセシング、翻訳に関与するタンパク質は、単独で、あるいは腫瘍タンパク質や成長因子を標的とするものと組み合わせて、前臨床試験で有望性が示されており、現在も試験が進行中です。さらに、異なる機能を持つ細胞周期タンパク質であるCDK4とCDK6は、いくつかのスクリーニングにおいて、融合型がんタンパク質とは無関係な潜在的標的として同定されています。CDK4およびCDK6阻害剤を再発ユーイング肉腫の化学療法レジメンに併用する試験が進行中です。

今後のユーイング肉腫治療市場情勢は、4価のデスレセプター5（DR5）アゴニスト抗体、CDK阻害剤、LSD1阻害剤、AXL阻害剤などの新しいクラスが登場した後、さらに拡大する見込みです。前世代のアゴニストの限界を克服し、DR5の活性化によって誘導される腫瘍特異的細胞死を利用するようにデザインされています。DR5は、三量体腫瘍壊死因子関連アポトーシス誘導リガンド（TRAIL）に対する2つのアポトーシス促進受容体のうちの1つです。

ユーイング肉腫の治療において、化学療法や外科的処置、放射線療法などの進歩により、生存率が向上した患者もいる一方で、進歩が停滞している患者もいます。高リスクのユーイング肉腫やその他の関連肉腫の管理については、主にその高リスクの生物学的特性についての理解が不完全であることと、発生頻度が比較的低いことから、依然として論争が続いています。これらの要因により、高リスクのユーイング肉腫患者や、よりまれな亜型の肉腫の少ない集団に対して包括的な臨床試験を実施することは困難です。

難治性または再発ユーイング肉腫に対する標準的な二次治療はありませんが、いくつかのレトロスペクティブ研究が従来の救済療法について報告しています。一般的な救済レジメンには、トポテカン、シクロホスファミド、イリノテカン、テモゾロミド、または大量化学療法（HDC）の後に造血幹細胞を再注入するものがあります。HDCと自家幹細胞移植（auto-SCT）の併用は、長年にわたって活発な関心、研究、議論の対象となってきました。複数のレトロスペクティブ研究や単群研究では、初期条件付け療法にばらつきがあるにもかかわらず、高リスク難治性ユーイング肉腫患者において有望な転帰が示されています。ユーイング肉腫におけるがん蛋白を標的とする他の潜在的戦略としては、RNA干渉、蛋白分解剤、新規エピトープを標的とする免疫療法などがあります。化学療法、放射線療法、手術療法などが現在のユーイング肉腫の治療法です。

今後期待される治療の開始、早期患者スクリーニングの統合化、2次医療やその他の臨床現場におけるユーイング肉腫の薬物療法、実施に最適な方法の調査、認知度の向上により、最終的には効果的な治療法の開発が促進されるであろう。ユーイング肉腫に対する有効な治療オプションが著しく不足していることは、この疾患への対応の進歩が緊急に必要であることを強調しています。しかし、ユーイング肉腫は希少疾病であるため、臨床試験を実施することが困難であり、そのため、この希少疾病に関する試験数を増やす努力が緊急に必要とされています。

• 主要7ヶ国のユーイング肉腫治療市場規模は2023年に約3,000万米ドルであり、予測期間中（2024～2034年）に拡大すると予測されています。
• EU4ヶ国カ国の中で、ユーイング肉腫の市場規模が最も大きいのはドイツで、EU4ヶ国全体と英国の市場シェアの25%を占めています。
• Seclidemstat+TCは、2034年までに2L+の新興治療法の中で最も高いユーイング肉腫市場シェアを獲得すると予想されます。
• 標的療法、免疫療法、併用療法を含む新規治療法の導入により、ユーイング肉腫の治療領域は拡大し、生存率の向上と化学療法や放射線療法などの従来の治療に伴う副作用の軽減が期待されます。

当レポートでは、主要7ヶ国におけるユーイング肉腫市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 報告書のイントロダクション

第3章 エグゼクティブサマリー

第4章 主要な出来事

第5章 疫学と市場予測の調査手法

第6章 ユーイング肉腫市場概要

• 2023年の治療法別市場シェア（％）分布
• 2034年の治療法別市場シェア（％）分布

第7章 疾患の背景と概要

• イントロダクション
• 原因
• 兆候と症状
• ステージング
  • TNMシステム
• リスク要因
• 病理学的診断
• 診断テスト
  • 画像検査
  • 外科的検査
  • その他の臨床検査

第8章 ユーイング肉腫の治療管理

• 治療アルゴリズム

第9章 ユーイング肉腫の治療ガイドライン

第10章 疫学と患者人口

• 主な調査結果
• 仮定と根拠
• 主要7ヶ国におけるユーイング肉腫の発生症例数
• 米国
• EU4ヶ国と英国
• 日本

第11章 患者動向

第12章 ユーイング肉腫の主要評価項目

第13章 新興薬剤

• 主な競合
• セクリデムスタット（SP-2577）：Salarius Pharmaceuticals
• ゼプゼルカ（ルルビネクテジン）：Jazz PharmaceuticalsとPharmaMar
• VERZENIO（アベマシクリブ）：Eli Lilly
• イブランス（パルボシクリブ）：Pfizer
• メクボタマブベドチン（BA3011）：BioAtla
• イオポホシンI 131（CLR 131）：Cellectar Biosciences
• TP-1287：Sumitomo Pharma Oncology
• INBRX-109：Inhibrx

第14章 ユーイング肉腫：主要7ヶ国分析

• 主な調査結果
• 市場見通し
• 主要な市場予測の前提条件
• コンジョイント分析
• 主要7ヶ国におけるユーイング肉腫の総市場規模
• 主要7ヶ国におけるユーイング肉腫の市場規模（治療法別）
• 米国市場規模
• EU4ヶ国と英国の市場規模
• 日本市場規模

第15章 アンメットニーズ

第16章 SWOT分析

第17章 KOLの見解

第18章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本
• 悪性骨腫瘍および肉腫の経済的負担

第19章 付録

第20章 Delveinsightのサービス内容

第21章 免責事項

List of Tables

TABLE 1: SUMMARY OF EWING SARCOMA MARKET AND EPIDEMIOLOGY (2020-2034)

TABLE 2: NCCN RECOMMENDED EWING SARCOMA CHEMOTHERAPY REGIMEN

TABLE 3: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE 7MM (2020-2034)

TABLE 4: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE US (2020-2034)

TABLE 5: AGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2020-2034)

TABLE 6: GENDER-SPECIFIC CASES OF EWING SARCOMA IN THE US (2020-2034)

TABLE 7: STAGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2020-2034)

TABLE 8: TOTAL INCIDENT CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

TABLE 9: AGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

TABLE 10: GENDER-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

TABLE 11: STAGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

TABLE 12: TOTAL INCIDENT CASES OF EWING SARCOMA IN JAPAN (2020-2034)

TABLE 13: AGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2020-2034)

TABLE 14: GENDER-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2020-2034)

TABLE 15: STAGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2020-2034)

TABLE 16: COMPARISON OF EMERGING DRUGS

TABLE 17: SECLIDEMSTAT, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 18: ZEPZELCA, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 19: VERZENIO, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 20: IBRANCE, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 21: MECBOTAMAB VEDOTIN, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 22: IOPOFOSINE I 131, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 23: TP-1287, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 24: INBRX-109, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 25: KEY MARKET FORECAST ASSUMPTION OF EWING SARCOMA IN THE US

TABLE 26: KEY MARKET FORECAST ASSUMPTION OF EWING SARCOMA IN EU4 AND THE UK

TABLE 27: KEY MARKET FORECAST ASSUMPTION OF EWING SARCOMA IN JAPAN

TABLE 28: TOTAL MARKET SIZE OF EWING SARCOMA IN THE 7MM, USD MILLION (2020-2034)

TABLE 29: MARKET SIZE OF EWING SARCOMA BY THERAPIES IN THE 7MM, USD MILLION (2020-2034)

TABLE 30: TOTAL MARKET SIZE OF EWING SARCOMA IN THE US, USD MILLION (2020-2034)

TABLE 31: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN THE US, USD MILLION (2020-2034)

TABLE 32: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE THERAPIES IN THE US, USD MILLION (2020-2034)

TABLE 33: TOTAL MARKET SIZE OF EWING SARCOMA IN EU4 AND THE UK, USD MILLION (2020-2034)

TABLE 34: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN EU4 AND THE UK, USD MILLION (2020-2034)

TABLE 35: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE THERAPIES IN EU4 AND THE UK, USD MILLION (2020-2034)

TABLE 36: TOTAL MARKET SIZE OF EWING SARCOMA IN JAPAN, USD MILLION (2020-2034)

TABLE 37: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN JAPAN, USD MILLION (2020-2034)

TABLE 38: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE THERAPIES IN JAPAN, USD MILLION (2020-2034)

List of Figures

FIGURE 1: SYMPTOMS OF EWING SARCOMA

FIGURE 2: TREATMENT ALGORITHM OF EWING SARCOMA

FIGURE 3: CURRENT TREATMENT ALGORITHM OF LOCALIZED EWING SARCOMA

FIGURE 4: CURRENT TREATMENT ALGORITHM OF METASTATIC EWING SARCOMA

FIGURE 5: NCCN RECOMMENDATION FOR EWING SARCOMA

FIGURE 6: NCCN RECOMMENDATION FOR EWING SARCOMA

FIGURE 7: NCCN GUIDELINE

FIGURE 8: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE 7MM (2020-2034)

FIGURE 9: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE US (2020-2034)

FIGURE 10: AGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2020-2034)

FIGURE 11: GENDER-SPECIFIC CASES OF EWING SARCOMA IN THE US (2020-2034)

FIGURE 12: STAGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2020-2034)

FIGURE 13: TOTAL INCIDENT CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

FIGURE 14: AGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

FIGURE 15: GENDER-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

FIGURE 16: STAGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2020-2034)

FIGURE 17: TOTAL INCIDENT CASES OF EWING SARCOMA IN JAPAN (2020-2034)

FIGURE 18: AGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2020-2034)

FIGURE 19: GENDER-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2020-2034)

FIGURE 20: STAGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2020-2034)

FIGURE 21: TOTAL MARKET SIZE OF EWING SARCOMA IN THE 7MM, USD MILLION (2020-2034)

FIGURE 22: MARKET SIZE OF EWING SARCOMA BY THERAPIES IN THE 7MM, USD MILLION (2020-2034)

FIGURE 23: TOTAL MARKET SIZE OF EWING SARCOMA IN THE US, USD MILLION (2020-2034)

FIGURE 24: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN THE US, USD MILLION (2020-2034)

FIGURE 25: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN THE US, USD MILLION (2020-2034)

FIGURE 26: TOTAL MARKET SIZE OF EWING SARCOMA IN EU4 AND THE UK, USD MILLION (2020-2034)

FIGURE 27: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN EU4 AND THE UK, USD MILLION (2020-2034)

FIGURE 28: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN THE EU4 AND THE UK, USD MILLION (2020-2034)

FIGURE 29: TOTAL MARKET SIZE OF EWING SARCOMA IN JAPAN, USD MILLION (2020-2034)

FIGURE 30: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN JAPAN, USD MILLION (2020-2034)

FIGURE 31: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN JAPAN, USD MILLION (2020-2034)

FIGURE 32: UNMET NEEDS

FIGURE 33: HEALTH TECHNOLOGY ASSESSMENT

FIGURE 34: REIMBURSEMENT PROCESS IN GERMANY

FIGURE 35: REIMBURSEMENT PROCESS IN FRANCE

FIGURE 36: REIMBURSEMENT PROCESS IN ITALY

FIGURE 37: REIMBURSEMENT PROCESS IN SPAIN

FIGURE 38: REIMBURSEMENT PROCESS IN THE UNITED KINGDOM

FIGURE 39: REIMBURSEMENT PROCESS IN JAPAN

FIGURE 40: TREATMENT PAYOR STATUS FOR BONE AND JOINTS CANCERS IN THE UNITED STATES (2004-2015)

Key Highlights:

• In 2023, the US accounted for the maximum share of the Ewing sarcoma Treatment Market in the 7MM, i.e., nearly 53%.
• A molecular-targeted therapy with minimal risk of late toxicities would be beneficial because most Ewing sarcoma Patients are under 20 years old.
• Although there is no standardized second-line treatment for refractory or relapsed Ewing sarcoma, several retrospective studies have reported on conventional salvage treatments.
• Chemotherapy and local therapy (surgery and/or radiation) are dominant in the Ewing sarcoma treatment at the moment.
• The adoption of the VDC/IE regimen has significantly increased survival. Patients with metastatic ES continue to experience negative outcomes, which will increase the demand for future therapeutics.
• The Ewing sarcoma Prognosis has improved over the years due to advances in treatment. The 5-year survival rate for localized Ewing sarcoma is around 70-80%, while the survival rate for metastatic disease is lower, around 30-40%. However, it is important to note that survival rates can vary depending on individual factors and the response to treatment.
• In the updated version 2.2023 of the NCCN guidelines lurbinectedin has been added as a second-line therapy option for Ewing sarcoma (for R/R or metastatic disease).
• Since no therapies are approved for Ewing sarcoma, there is a significant market opportunity for the companies to enter this space and get the first-mover advantage.
• Targeted Ewing Sarcoma Treatments, immunotherapies, precision oncology, and other novel treatments are used to treat some cancer types, but chemotherapy is still the mainstay of treatment for many sarcoma subtypes. There are either none or very few approved drugs for treating many subtypes of sarcoma that can be effectively given to patients, especially after disease progression.
• The usage of off-label therapies may hamper the uptake of new therapies.
• First-line therapy for Metastatic Ewing Sarcoma is similar to that for localized disease and utilizes the same chemotherapy backbone with adequate local control of both primary and metastatic sites.
• The development of Ewing sarcoma Therapies is primarily undertaken by prominent Ewing Sarcoma Companies, including Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, BioAlta, Inhibrx, and others. These key Ewing Sarcoma Companies focus on developing treatments specifically for patients in the second line (2L) and above of treatment
• Due to a potential unexpected significant adverse reaction (SUSAR), Salarius voluntarily stopped enrolling new patients in its Phase I/II trial of seclidemstat as a therapy for Ewing sarcoma last year. The FDA ended its examination of the company's application for seclidemstat in May 2023 and declared that the clinical trial might be restarted.

DelveInsight's "Ewing Sarcoma Treatment Drugs Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology as well as Ewing Sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Ewing Sarcoma Treatment Market Report provides current treatment practices, emerging drugs, Ewing Sarcoma market share of individual therapies, and current and forecasted 7MM Ewing Sarcoma market size from 2020 to 2034. The report also covers current Ewing Sarcoma treatment drugs market practices/algorithms and Ewing Sarcoma unmet medical needs to curate the best opportunities and assess the market's potential.

Ewing Sarcoma Treatment Market

Ewing sarcoma (also known as Ewing's sarcoma) is a cancerous tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing's sarcoma can develop in any bone, it usually affects the long bones, such as the thighbone (femur), shinbone (tibia), and upper arm bone (humerus). The bones of the pelvis are also often affected. Occasionally, the tumor begins in the muscles and soft tissues. The most common symptoms are stiffness, pain, swelling, or tenderness in the bone or the tissue surrounding the bone.

Ewing Sarcoma Diagnosis

The patient's journey begins with symptoms such as persistent bone pain even at rest, swelling, and a large palpable mass on the affected bone. Followed by a visit to the orthopedist, where the patient is suggested diagnostic tests such as MRI, CT scan, and plain radiography. After the diagnosis patient is referred to an oncologist for further treatment. A tissue biopsy is performed of the mass removed from the most aggressive portion of cancer as determined by imaging for confirmatory diagnosis. Once Ewing Sarcoma is confirmed, relevant treatment is given to the patient.

Ewing Sarcoma Treatment

The Ewing sarcoma treatment typically involves a multidisciplinary approach, including surgery, chemotherapy, and radiation therapy. NCCN recommended different chemotherapy combinations to treat localized and metastatic Ewing sarcoma. VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) are recommended by NCCN in the first line and as primary therapy for metastatic disease at initial presentation. For second-line treatment Cyclophosphamide and topotecan, Irinotecan + temozolomide +- NCCN recommends Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin.

Ewing Sarcoma Epidemiology

As the market is derived using a patient-based model, the Ewing Sarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total Ewing Sarcoma Incidence Cases, gender-specific cases of Ewing Sarcoma, age-specific cases of Ewing Sarcoma, and stage-specific cases of Ewing Sarcoma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034. The total incident cases of Ewing sarcoma in the 7MM comprised approximately 1,200 cases in 2023 and are projected to increase during the forecasted period.

• In the 7MM, the highest Ewing Sarcoma Incidence Cases were seen in the United States, accounting of ~41% of the total cases.
• In the EU4, Germany accounted for the highest Ewing sarcoma cases accounting of ~15% of the total cases, , whereas Italy accounted for the lowest.
• In the US, among all the age groups, 10-14 years accounted for the highest number of Ewing sarcoma cases i.e., around 30%, followed by the age-group 15-19 years (26%), in 2023.
• As per the analysis, males are more likely to get Ewing Sarcoma than females. In the US, in 2023, ~300 incident cases of male Ewing Sarcoma were estimated.

Ewing Sarcoma Recent Developments

• On November 12, 2024, Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to elraglusib, a novel glycogen synthase kinase-3 beta (GSK-3B) inhibitor, for the treatment of Ewing sarcoma (EWS).
• On November 12, 2024, the FDA granted rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3B inhibitor, as a potential treatment for patients with Ewing sarcoma.

Ewing Sarcoma Treatment Drugs Market Chapters

The drug chapter segment of the Ewing Sarcoma treatment drugs market report encloses a detailed analysis of the late-stage (Phase II) and Early stage (Phase I/II) Ewing Sarcoma pipeline drug analysis such Seclidemstat (SP-2577), lurbinectedin, Mecbotamab Vedotin (BA3011), and others. There are currently no approved Ewing Sarcoma therapies. It also helps understand the Ewing Sarcoma clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest Ewing Sarcoma news and press releases.

Ewing Sarcoma Emerging Drugs Profile

• Seclidemstat: Salarius Pharmaceuticals

Seclidemstat (SP-2577) inhibits LSD1's enzymatic activity and its scaffolding function. SP-2577 is being studied in an ongoing Phase I/II trial in Ewing sarcoma. Salarius is studying the combination of SP-2577 with topotecan and cyclophosphamide (TC), two agents are commonly given as second or third-line therapy, to improve patient outcomes over TC alone.

• In October 2022, the company voluntarily paused new patient enrollment in its Phase I/II trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas per protocol design. The pause in new patient enrollment was due to a metastatic FET-rearranged sarcoma patient death classified as a suspected unexpected serious adverse reaction (SUSAR).
• Later, in May 2023, the company was notified by FDA that they had completed the review of the company's submission and had concluded that the Ewing Sarcoma clinical trial may be resumed.
• ZEPZELCA (Lurbinectedin): Jazz Pharmaceuticals and PharmaMar

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent.

• In December 2019, PharmaMar and Jazz Pharmaceuticals announced that PharmaMar and Jazz Pharmaceuticals had entered into an exclusive license agreement for lurbinectedin in the United States.
• In the updated version 2.2023 of the NCCN guidelines lurbinectedin has been added as a second-line therapy option for Ewing sarcoma (for R/R or metastatic disease). Under category 2B, this is useful in certain circumstances recommendation.

Ewing Sarcoma Treatment Drugs Market Insights

CDK inhibitors: Proteins involved in RNA transcription, processing, and translation, such as CDK9, CDK12, and CDK13, have shown preclinical promise either alone or in combination with oncoprotein or growth factor targeting, with ongoing trials. Furthermore, CDK4 and CDK6, cell cycle proteins with different functions, have been identified as potential targets unrelated to the fusion oncoprotein in several screens. Trials testing CDK4 and CDK6 inhibitors combined with relapsed Ewing sarcoma Chemotherapy regimens are underway.

The upcoming Ewing Sarcoma Treatment Market Landscape is poised to expand further after new classes, such as tetravalent death receptor 5 (DR5) agonist antibodies, CDK inhibitors, LSD1 inhibitors, AXL inhibitors, and others. Designed to overcome the limitations of earlier-generation agonists and exploit the tumor-specific cell death induced by DR5 activation. DR5 is one of two pro-apoptotic receptors for the trimeric tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Ewing Sarcoma Market Outlook

While advancements in the Ewing Sarcoma treatment, such as chemotherapy and surgical procedures along with radiation therapy, have resulted in better survival rates for some patients, progress has been stagnant for others. The management of high-risk Ewing Sarcoma and other related sarcomas remains controversial, primarily due to an incomplete understanding of their high-risk biological characteristics and relatively low occurrence. These factors have made it challenging to conduct comprehensive clinical trials for the smaller populations of high-risk Ewing Sarcoma patients and the rarer subtypes of sarcomas.

Although there is no standardized second-line treatment for refractory or relapsed Ewing sarcoma, several retrospective studies have reported on conventional salvage treatments. Common salvage regimens involve topotecan, cyclophosphamide, irinotecan, temozolomide, or high-dose chemotherapy (HDC) followed by reinfusion of hematopoietic stem cells. The use of HDC combined with autologous stem cell transplantation (auto-SCT) has been an area of active interest, investigation, and debate for many years. Multiple retrospective and single-arm studies, despite variations in initial conditioning therapy, have shown promising outcomes in patients with high-risk and refractory Ewing Sarcoma. Other potential strategies to target the oncoprotein in Ewing sarcoma include RNA interference, protein degraders, and immunotherapy directed at the novel epitope. Chemotherapy, radiation, surgery, and others are the current Ewing Sarcoma treatment options.

The expected launch of upcoming therapy and greater integration of early patient screening, Ewing Sarcoma medication in secondary care and other clinical settings, research on best methods for implementation, and an upsurge in awareness will eventually facilitate the development of effective treatment options. The significant lack of effective treatment options for Ewing sarcoma underscores the urgent need for advancements in addressing this disease. However, since Ewing Sarcoma is an orphan disease, it is difficult to conduct clinical trials, hence, efforts to increase the number of studies on this orphan disease are urgently needed.

• The Ewing Sarcoma Treatment Market Size in the 7MM is approximately USD 30 million in 2023 and is projected to increase during the forecast period (2024-2034).
• Among EU4 countries, Germany accounts for the maximum Ewing Sarcoma market size i.e. ~25% of the total EU4 and the UK market share.
• Seclidemstat + TC is expected to capture the highest Ewing Sarcoma market share among emerging therapies in the 2L+ setting by 2034.
• The introduction of novel treatment options, including targeted therapies, immunotherapies, and combination regimens, will expand the treatment landscape for Ewing sarcoma to improve survival rates and reduce the side effects associated with traditional treatments like chemotherapy and radiation therapy.

Ewing Sarcoma Drugs Uptake

This section focuses on the uptake rate of potential Ewing Sarcoma drugs expected to be launched in the market during 2020-2034. Salarius Pharmaceuticals is currently working on the development of Seclidemstat as a potential Ewing Sarcoma treatment. This drug is anticipated to be well-received with fast uptake, with a projected probability-adjusted peak share of ~42% in the United States for patients in the second line of treatment and beyond.

Ewing Sarcoma Pipeline Development Activities

The Ewing Sarcoma pipeline segement provides insights into therapeutic candidates in Phase II and Phase I stage. It also analyzes key Ewing Sarcoma Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Ewing Sarcoma pipeline segment covers information on collaborations, acquisitions and mergers, licensing, and patent details for Ewing Sarcoma's emerging therapy.

KOL Views

To keep up with current Ewing Sarcoma Pipeline Drugs Market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on evolving Ewing Sarcoma treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Oncologists; Orthopedists, and Professors; MD, FACS, Chair of the Department of Orthopedic Surgery, and professor at UC Davis Comprehensive Cancer Center in Sacramento, California; MD, Director, Sarcoma Oncology Center, California; and others.

Delveinsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Sarcoma Oncology Center, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Ewing Sarcoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and Ewing Sarcoma Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving Ewing Sarcoma treatment landscape.

The analyst views analyze multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in Ewing Sarcoma trials, progression-free survival is one of the most important primary outcome measures. Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Ewing Sarcoma Therapeutics Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers' concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently. Overall, treatment for bone and joint cancers can easily exceed USD 100,000 for a single patient. This is particularly true if a patient receives surgery, chemotherapy, and radiation therapy. The cost will be much higher if one includes bone-replacing endoprostheses or artificial limbs used in cases requiring amputation.

The Ewing Sarcoma Clinical Trials Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Ewing Sarcoma Therapeutics Market Report Scope

• The Ewing Sarcoma Therapeutics Market Report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the Ewing Sarcoma epidemiology segments and forecasts, disease progression, and Ewing Sarcoma treatment guidelines has been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Ewing Sarcoma Treatment Market Landscape.
• A detailed review of the Ewing Sarcoma Pipeline Drugs Market, historical and forecasted Ewing Sarcoma market size, Ewing Sarcoma market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The patient-based Ewing Sarcoma Market Forecasting report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Ewing Sarcoma Therapeutics Market.

Ewing Sarcoma Therapeutics Market Report Insights

• Patient-based Ewing Sarcoma Market Forecasting
• Therapeutic Approaches
• Ewing Sarcoma Pipeline Drugs Analysis
• Ewing Sarcoma Market Size
• Ewring Sarcoma Market Trends
• Existing and Future Ewing Sarcoma Pipeline Drugs Market Opportunity

Ewing Sarcoma Therapeutics Market Report Key Strengths

• 11 Years Ewing Sarcoma Market Forecast
• The 7MM Coverage
• Ewing Sarcoma Epidemiology Segmentation
• Key Cross Competition
• Ewring Sarcoma Pipeline Drugs Uptake
• Key Ewing Sarcoma Market Forecast Assumptions

Ewing Sarcoma Treatment Market Report Assessment

• Current Ewing Sarcoma Treatment Market Practices
• Ewing Sarcoma Unmet Needs
• Ewing Sarcoma Pipeline Drugs Analysis Profiles
• Ewing Sarcoma Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

Key Questions:

Ewing Sarcoma Treatment Market Insights

• What was the Ewing Sarcoma market size, the market size by therapies, Ewing Sarcoma market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• What will be the impact of Seclidemstat's expected approval by 2025?
• How would CDK inhibitors perform as a class in the second line?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Ewing Sarcoma Epidemiology Insights

• What are the disease risk, burdens, and Ewing Sarcoma unmet needs? What will be the growth opportunities across the 7MM concerning the patient population with Ewing Sarcoma?
• What is the historical and forecasted Ewing Sarcoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which gender has a higher Ewing Sarcoma Incidence?
• How many Ewing Sarcoma patients are diagnosed with localized or metastatic disease?
• Which age group of Ewing Sarcoma has a high patient share?

Current Ewing Sarcoma Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the Ewing Sarcoma treatment? What are the current guidelines for treating Ewing Sarcoma in the US and Europe?
• How many companies are developing therapies for the Ewing Sarcoma treatment?
• How many emerging therapies are in the mid-stage and late stage of development for treating Ewing Sarcoma?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What key designations have been granted for the emerging therapies for Ewing Sarcoma?
• What is the cost burden of current therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, current therapies? Focusing on the reimbursement policies.
• What is the 7MM historical and forecasted Ewing Sarcoma Drugs Market?

Reasons to Buy:

• The Ewing Sarcoma market outlook report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Ewing Sarcoma Pipeline Drugs Market.
• Insights on patient burden/disease Ewing Sarcoma Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Ewing Sarcoma Pipeline Drugs Market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Ewing Sarcoma Pipeline Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing Ewing Sarcoma Clinical Trials Market so that the upcoming Ewing Sarcoma companies can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2 Report Introduction

3 Executive Summary of Ewing Sarcoma

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Ewing Sarcoma Market Overview at a Glance

• 6.1 Market Share (%) Distribution by Therapies in 2023
• 6.2 Market Share (%) Distribution by Therapies in 2034

7 Disease Background and overview

• 7.1 Introduction
• 7.2 Causes
• 7.3 Signs and Symptoms
• 7.4 Staging
  • 7.4.1 The TNM System
• 7.5 Risk Factors
• 7.6 Pathological Diagnosis
• 7.7 Diagnostic Tests
  • 7.7.1 Imaging Tests
  • 7.7.2 Surgical Tests
  • 7.7.3 Other Laboratory Tests

8 Treatment Management of Ewing Sarcoma

• 8.1 Treatment Algorithm

9 Treatment Guidelines for Ewing Sarcoma

• 9.1 NCCN Guidelines: 2023
• 9.2 Ewing Sarcoma: ESMO-PAEDCAN-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and follow-up
• 9.3 Japan Guideline

10 Epidemiology and Patient Population

• 10.1 Key findings
• 10.2 Assumptions and Rationale
• 10.3 Total Incident Cases of Ewing Sarcoma in the 7MM
• 10.4 The United States
  • 10.4.1 Total Incident Cases of Ewing Sarcoma in the United States
  • 10.4.2 Age-specific Cases of Ewing Sarcoma in the United States
  • 10.4.3 Gender-specific Cases of Ewing Sarcoma in the United States
  • 10.4.4 Stage-specific Cases of Ewing Sarcoma in the United States
• 10.5 EU4 and the UK
  • 10.5.1 Total Incident Cases of Ewing Sarcoma in EU4 and the UK
  • 10.5.2 Age-specific Cases of Ewing Sarcoma in EU4 and the UK
  • 10.5.3 Gender-specific Cases of Ewing Sarcoma in EU4 and the UK
  • 10.5.4 Stage-specific Cases of Ewing Sarcoma in EU4 and the UK
• 10.6 Japan
  • 10.6.1 Total Incident Cases of Ewing Sarcoma in Japan
  • 10.6.2 Age-specific Cases of Ewing Sarcoma in Japan
  • 10.6.3 Gender-specific Cases of Ewing Sarcoma in Japan
  • 10.6.4 Stage-specific Cases of Ewing Sarcoma in Japan

11 Patient Journey

12 Key Endpoints in Ewing Sarcoma

13 Emerging Drugs

• 13.1 Key Competitors
• 13.2 Seclidemstat (SP-2577): Salarius Pharmaceuticals
  • 13.2.1 Product Description
  • 13.2.2 Other Development Activities
  • 13.2.3 Clinical Development
    • 13.2.3.1 Clinical Trials Information
  • 13.2.4 Safety and Efficacy
• 13.3 Zepzelca (Lurbinectedin): Jazz Pharmaceuticals and PharmaMar
  • 13.3.1 Product Description
  • 13.3.2 Other Development Activities
  • 13.3.3 Clinical Development
    • 13.3.3.1 Clinical Trials Information
  • 13.3.4 Safety and Efficacy
• 13.4 VERZENIO (abemaciclib): Eli Lilly
  • 13.4.1 Product Description
  • 13.4.2 Clinical Development
    • 13.4.2.1 Clinical Trials Information
• 13.5 IBRANCE (palbociclib): Pfizer
  • 13.5.1 Product Description
  • 13.5.2 Clinical Development
    • 13.5.2.1 Clinical Trials Information
• 13.6 Mecbotamab Vedotin (BA3011): BioAtla
  • 13.6.1 Product Description
  • 13.6.2 Other Development Activities
  • 13.6.3 Clinical Development
    • 13.6.3.1 Clinical Trials Information
• 13.7 Iopofosine I 131 (CLR 131): Cellectar Biosciences
  • 13.7.1 Product Description
  • 13.7.2 Other Development Activities
  • 13.7.3 Clinical Development
    • 13.7.3.1 Clinical Trials Information
• 13.8 TP-1287: Sumitomo Pharma Oncology
  • 13.8.1 Product Description
  • 13.8.2 Other Development Activities
  • 13.8.3 Clinical Development
    • 13.8.3.1. Clinical Trials Information
• 13.9 INBRX-109: Inhibrx
  • 13.9.1 Product Description
  • 13.9.2 Clinical Development
    • 13.9.2.1 Clinical Trials Information

14 Ewing Sarcoma: The 7MM Analysis

• 14.1 Key Findings
• 14.2 Market Outlook
• 14.3 Key Market Forecast Assumptions
• 14.4 Conjoint Analysis
• 14.5 Total Market Size of Ewing Sarcoma in the 7MM
• 14.6 Market Size of Ewing Sarcoma by Therapies in the 7MM
• 14.7 United States Market Size
  • 14.7.1 Total Market Size of Ewing Sarcoma in the United States
  • 14.7.2 Market Size of Ewing Sarcoma by First-line Therapies in the United States
  • 14.7.3 Market Size of Ewing Sarcoma by Second-line and Above Therapies in the United States
• 14.8 EU4 and the UK Market Size
  • 14.8.1 Total Market Size of Ewing Sarcoma in EU4 and the UK
  • 14.8.2 Market Size of Ewing Sarcoma by First-line Therapies in EU4 and the UK
  • 14.8.3 Market Size of Ewing Sarcoma by Second-line and Above Therapies in EU4 and the UK
• 14.9 Japan Market Size
  • 14.9.1 Total Market Size of Ewing Sarcoma in Japan
  • 14.9.2 Market Size of Ewing Sarcoma by First-line Therapies in Japan
  • 14.9.3 Market Size of Ewing Sarcoma by Second-line and Above Therapies in Japan

15 Unmet Needs

16 SWOT Analysis

17 KOL Views

18 Market Access and Reimbursement

• 18.1 The United States
  • 18.1.1 Centre for Medicare & Medicaid Services (CMS)
• 18.2 EU4 and the UK
  • 18.2.1 Germany
  • 18.2.2 France
  • 18.2.3 Italy
  • 18.2.4 Spain
  • 18.2.5 United Kingdom
• 18.3 Japan
  • 18.3.1 MHLW
• 18.4 Economic Burden of Malignant Bone Tumors and Sarcomas

19 Appendix

• 19.1 Bibliography
• 19.2 Report Methodology

20 Delveinsight Capabilities

21 Disclaimer